Substitution therapy of parkinsonism. Insufficient results with 3-0-methyldopa
Ajuriaguerra, J.; Gauthier, G.; Geissbuhler, F.; Simona, B.; Constantinidis, J.; Yanniotis, G.; Krassoievitch, M.; Eisenring, J.; Tissot, R.
La Presse Medicale 79(30): 1396
1971
ISSN/ISBN: 0032-7867 PMID: 5093018 Document Number: 34389
Document emailed within 1 workday
Related Documents
Yahr, M.D.; Duvoisin, R.C.; Mendoza, M.R.; Schear, M.J.; Barrett, R.E. 1971: Modification of L-dopa therapy of Parkinsonism by alpha-methyldopa hydrazine (MK-486) Transactions of the American Neurological Association 96: 55-58Simek, I.; Duda, M.; Kubias, K. 1993: Substitution therapy in insufficient external pancreatic secretion Vnitrni Lekarstvi 39(3): 250-252
Ciammella, M.; Guareschi, B.; Pes, S.; Cocucci, C.; Nencioni, T. 1993: Substitution estrogen therapy in the prevention of postmenopausal osteoporosis and cardiovascular diseases. Results of long-term therapy Minerva Ginecologica 45(1-2): 53-55
Campbell, N.R.; Campbell, R.R.; Hasinoff, B.B. 1990: Ferrous sulfate reduces methyldopa absorption: methyldopa: iron complex formation as a likely mechanism Clinical and Investigative Medicine. Medecine Clinique et Experimentale 13(6): 329-332
Schwartz-Porsche, D. 1992: Insufficient success in the treatment of epilepsy--mistakes in therapy or resistance to therapy? Deutsche Tierärztliche Wochenschrift 99(10): 407-410
Boissonnas, A. 1994: How to treat a patient with AIDS and drug dependence unwilling and/or unable to withdraw? Give substitution drugs at the hospital? Should substitution be continued after discharge? Is substitution a useful adjuvant to programs designed to prevent opportunistic diseases?] opportunisticinfections? Annales de Medecine Interne 145 Suppl. 3: 54-55
Peterson, S.H. 1977: Arthralgia as a side effect of methyldopa therapy Journal of the American Osteopathic Association 76(5): 376
Koller, O.; Lehoczky, D. 1976: Immune hemolysis in the course of alpha methyldopa therapy Orvosi Hetilap 117(9): 545-546
Muenter, M.D.; Sharpless, N.S.; Tyce, G.M. 1972: Plasma 3-0-methyldopa in L-dopa therapy of Parkinson's disease Mayo Clinic Proceedings 47(6): 389-395
Whelton, P.K.; Russell, R.P.; Sova-Schulz, K.; Wyndham, R.; Walker, W.G. 1979: Comparison of prazosin and methyldopa in essential hypertension: results of a randomized, double-blind, parallel trial Journal of Cardiovascular Pharmacology 1(6 Suppl): S28-S37
Rosendorff, C. 1982: Guanabenz versus methyldopa in the therapy of mild-to-moderate hypertension South African Medical Journal 62(13): 435-437
Rosenkvist, J.; Dybkjaer, E. 1990: False negative results in anti-HIV ELISA due to insufficient antigen coating of microtitre plates Medical Laboratory Sciences 47(4): 353-355
Kiene, S.; Kropf, G. 1991: Possibilities for reconstructing the insufficient anal sphincter and assessment of results by anorectal stress profile Zentralblatt für Chirurgie 116(9): 559-573
Hellinger, J.; Soukup, P.; Walch, H.; Kühn, R.; Graner, H. 1972: Insufficient diagnosis and therapy in nucleus pulposus prolapse Zeitschrift für Arztliche Fortbildung 66(24): 1249-1251
Paal, G. 1973: Therapy of parkinsonism Die Medizinische Welt 24(15): 573-576
Pakkenberg, H. 1973: Amantadine therapy in parkinsonism Ugeskrift for Laeger 135(3): 135-136
Jörg, J. 1975: Therapy of parkinsonism using L-Dopa (Brocadopa) Die Medizinische Welt 26(3): 124-126
Schutter, U.; Ritzdorf, I.; Heckes, B. 2010: The transdermal 7-day buprenorphine patch--an effective and safe treatment option, if tramadol or tilidate/naloxone is insufficient. Results of a non-interventional study MMW Fortschritte der Medizin 152(Suppl 2): 62-69
De Divitiis, E.; Cerillo, A.; Tata, M.R.; Decina, A. 1973: Therapeutic association of L-dopa and an inhibitor of peripheral decarboxylase in Parkinsonism. Preliminary results Acta Neurologica 28(2): 208-212
Bhaskar, P.A.; Bhaskar, E.A.; Jagannathan, K. 1975: Augmenting procedures during L-dopa therapy for Parkinsonism Journal of the Association of Physicians of India 23(1): 21-27